Skip to main content
ARS Home » Research » Publications at this Location » Publication #248246
Title: Serologic cross reactivity of serum samples from avian influenza vaccinated commercial U.S. turkeys to the emergent H1N1 influenza virus

Author
item Kapczynski, Darrell
item GONDER, ERIC - Goldsboro Milling
item TILLEY, BECKY - Goldsboro Milling
item Suarez, David
item Swayne, David

Submitted to: Western Poultry Disease Conference
Publication Type: Abstract Only
Publication Acceptance Date: 1/30/2010
Publication Date: 4/18/2010
Citation: Kapczynski, D.R., Gonder, E., Tilley, B., Suarez, D.L., Swayne, D.E. 2010. Serologic cross reactivity of serum samples from avian influenza vaccinated commercial U.S. turkeys to the emergent H1N1 influenza virus [abstract]. Western Poultry Disease Conference. April 18-21, 2010, Vancouver, BC, Canada. CDROM.

Interpretive Summary:

Technical Abstract: Recently, the 2009 human H1N1 influenza virus was identified in turkey breeders in Chile and Canada resulting in infection and egg production losses. In the U.S., vaccination of turkeys against avian influenza may include H1 and H3 viruses also isolated from swine. We tested whether sera from turkeys vaccinated against avian H1N1 would cross react against the recent human pandemic H1N1. Turkey breeders received three vaccinations with a trivalent inactivated autogenous vaccine which contained 2 H1N1 strains of avian origin. Genetic testing indicated greater than 92 percent nucleotide similarity in hemagglutinin gene sequence between one of the vaccine isolates and the human H1. High levels of HI antibody were observed against the avian influenza vaccine viruses. In contrast, minimal cross reaction against the human isolate was observed. Taken together, these studies suggest the current turkey H1N1 vaccines may have limited cross protection against the human pandemic H1N1.